



MiP Pharma Group on track for growth Forward-looking investments at the Homburg site

Blieskastel, 21.10.2021. MiP Pharma Group is expanding its production capacities as well as laboratory and office space at its Homburg site. The significant investments underline the growth path of the company and create new jobs in the medium term.

MiP Pharma Group produces and distributes prescription generics, especially antibiotics, over-the-counter medicines and medical products. With the expansion of the Homburg site, the company is strengthening its production capacities in future-oriented technologies such as sterile production.

Dr. Friedrich Sernetz, CEO of MiP Pharma Group, explains: "The significant investments at the Homburg site are important steps on MiP Pharma's growth path, which we are consistently pursuing. We are modernizing and expanding our German production capacities with a focus on highly specialized pharmaceutical manufacturing processes in sterile production. By doing so, we are strengthening both the production chain for a large number of our own products and our ambitions as a qualified contract manufacturer for particularly demanding products – e.g. for parenteral dosage forms of antibiotics, vaccines or biotechnological products. The expansion will also create new, future-oriented jobs in Homburg in the medium term."

In the context of the investment program, all activities and jobs will be relocated from the St. Ingbert site to MiP Pharma's future single production site in Homburg by 2023. The production expansion there will be implemented by enlarging the available space resources in the existing production building.

Alexander Zamora, partner at MiP Pharma Group's owner capiton AG, affirms: "We support MiP Pharma Group in leveraging its growth opportunities and provide the necessary capital. Since the acquisition by us at the end of last year, MiP Pharma Group has shown a positive development. This strengthens our approach."

Dr Friedrich Sernetz continues: "We are actively seizing our growth opportunities and investing in the future of our company. We want to grow together with our employees and are committed to ensuring that, with the help of all employees, the relocation from St. Ingbert to Homburg as well as the further expansion of our production capacities on site will go smoothly."



About MiP Pharma Group

MiP Pharma Group (MiP Pharma) produces and distributes prescription generics, especially antibiotics, over-the-counter medicines and medical products. Its main markets are Germany and Poland as well as some other Eastern European markets. Sales focus the hospital business and selected groups of specialists and, in particular, dentists. MiP Pharma operates two production sites in Saarland/Germany. With over 250 employees and around 400 regulatory approvals, MiP Pharma generated total sales of over € 40 million in the last fiscal year. Since November 2020, previously family-run MiP Pharma has been a portfolio company of the Berlin-based financial investor capiton AG.

Media Contact

Evelyn Gilde-Back

+49 176 636 13 964

evelyn@backroberts.com